Lonafarnib

Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones

Retrieved on: 
Thursday, January 6, 2022
Clinical trial, CHMP, COVID-19, PALO, Degenerative disease, Patient, Forward-looking statement, Lonafarnib, Compte rendu, Risk, Private Securities Litigation Reform Act, CEO, Congenital hyperinsulinism, SEC, FDA, Hepatitis, Nasdaq, Biopharmaceutical, Investment, Pharmaceutical industry, HDV, EU, Eiger

PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ --Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones.

Key Points: 
  • PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ --Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones.
  • "This is a pivotal year for Eiger as we plan for topline data from the landmark D-LIVR study by year end.
  • D-LIVR is the largest trial conducted in HDV and if positive will support regulatory filings for Lonafarnib-based regimens," said David Cory, President and CEO of Eiger.
  • "HDV is a large unmet medical need with over 12 million people suffering from this devastating disease around the globe.

Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15

Retrieved on: 
Tuesday, November 2, 2021
KOL, Cirrhosis, MD, Research, AASLD, Diagnosis, University, Ben-Gurion University of the Negev, Disease, Association, Institute of Liver and Biliary Sciences, Lonafarnib, Global health, PALO, AM, Outline of health sciences, III, Faculty, Patient, American Association for the Study of Liver Diseases, Liver cancer, Hepatitis B virus, HBsAg, Center, McMaster Faculty of Health Sciences, Liver disease, Non-alcoholic fatty liver disease, International, Company, Transplant, Viral hepatitis, Investor relations, Eiger, Fondazione Child, American Association, Therapy, Liver failure, HDV, Coinfection, Doctor of Philosophy, University of Milan, HBV, Department, Pharmaceutical industry, Medicine, Fine chemical, Vaccine

PALO ALTO, Calif., Nov. 2, 2021 /PRNewswire/ --Eiger BioPharmaceuticals, Inc.(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announcedthat it will host a virtual Key Opinion Leader (KOL) event focused on Hepatitis Delta Virus (HDV) infection.

Key Points: 
  • PALO ALTO, Calif., Nov. 2, 2021 /PRNewswire/ --Eiger BioPharmaceuticals, Inc.(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announcedthat it will host a virtual Key Opinion Leader (KOL) event focused on Hepatitis Delta Virus (HDV) infection.
  • The event is scheduled to take place on Monday, November 15, 2021 from9:00-10:30 AM ETand will be simultaneously webcast.
  • The live and replayed webcast of the event will be available through the Investor Relations "Events & Presentations" section of the company's website at www.eigerbio.com .
  • His most recent project involves treatment of hepatitis Delta patients with Lonafarnib and Peginterferon Lambda.

Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2021 Financial Results and Business Update on Thursday, November 4

Retrieved on: 
Thursday, October 21, 2021
International, HDV, Viral hepatitis, Webcast, III, Lonafarnib, PALO, Fine chemical, Pharmaceutical industry

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com .

Key Points: 
  • The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com .
  • To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 9874006.
  • The webcast will be archived and available for replay for at least 90 days after the event.
  • Eigeris a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.

Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer

Retrieved on: 
Tuesday, September 21, 2021
Privacy, Review, Compliance, Compte rendu, Harvard University, Risk, Georgetown University Law Center, Lawyer, III, FDA, Patient, Labour law, Employment, Amneal Pharmaceuticals, Eiger, Cytokinetics, MAA, University, Company, B.A, Terminology, Growth, HDV, PALO, Commercial, Health care, Lonafarnib, EMA, General counsel, Senior counsel, Viral hepatitis, University of Edinburgh, SEC, HGPS, Fine chemical, Management, Pharmaceutical industry

PALO ALTO, Calif., Sept.21, 2021 /PRNewswire/ --Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Erik Atkisson as the Company's General Counsel and Chief Compliance Officer.

Key Points: 
  • PALO ALTO, Calif., Sept.21, 2021 /PRNewswire/ --Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Erik Atkisson as the Company's General Counsel and Chief Compliance Officer.
  • Mr. Atkisson brings over twenty years of experience to Eiger, and was most recently Chief Compliance Officer, Legal Counsel, and Privacy Officer at Cytokinetics, Incorporated, where he was responsible for legal matters related to corporate securities, licensing, partnerships and collaborations, and compliance.
  • Previously, Mr. Atkisson was Deputy General Counsel and Compliance Counsel at Nevro, Corp., Senior Director, Commercial, Healthcare and Employment Law at Impax Laboratories, Inc., and Senior Counsel at BioMarin Pharmaceutical Inc. Mr. Atkisson began his legal career as an associate at international law firms with a practice focused on life sciences.
  • "This is an exciting time as Eiger advances multiple late-stage, breakthrough therapy designated programs," said Erik Atkisson.

Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism

Retrieved on: 
Thursday, August 5, 2021
MD, Learning, Brain damage, Insulin, Lists of diseases, Hyperinsulinemic hypoglycemia, Pancreas, Viral hepatitis, Review, HI, Patient, Eiger, Inborn errors of metabolism, EMA, LILO (boot loader), Metabolic disorder, Food and Drug Administration, Hepatitis, Congenital hyperinsulinism, Risk, Lonafarnib, III, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Compliance, Death, Fasting, Birth defect, Hypoglycemia, Paro Airport, Food, HDV, Pharmaceutical industry

Eiger's application was supported by data from three completed Phase 2 studies in 39 neonates, children and adolescents with congenital hyperinsulinism.

Key Points: 
  • Eiger's application was supported by data from three completed Phase 2 studies in 39 neonates, children and adolescents with congenital hyperinsulinism.
  • "Avexitide represents a promising, targeted approach for the treatment of congenital hyperinsulinism, an urgent, unmet medical need with no approved therapy," said Colleen Craig, MD, Vice President of Metabolic Diseases at Eiger.
  • Avexitide has been granted Breakthrough Therapy Designation by the FDA for the treatment of congenital hyperinsulism, Orphan Drug Designation by the FDA for the treatment of hyperinsulinemic hypoglycemia (which includes congenital hyperinsulinism), Orphan Drug Designation by the EMA for the treatment of congenital hyperinsulinism and Rare Pediatric Disease Designation by the FDA.
  • Avexitide has been granted Breakthrough Therapy Designation by the FDA, as well as Orphan Drug Designation by the FDA for the treatment of hyperinsulinemic hypoglycemia and Orphan Drug Designation by the EMA for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS).

Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Life sciences, Health, Senescence, Progeroid syndromes, Genodermatoses, Rare diseases, Laminopathy, Muscular dystrophy, Lonafarnib, Progeria, HGPS

A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.

Key Points: 
  • A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.
  • A replay of the webcast will be available approximately one hour following the live event.
  • Eigeris a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
  • Zokinvyfor the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product.

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Organic compounds, Chemical compounds, Senescence, Genodermatoses, Progeroid syndromes, Rare diseases, Laminopathy, Muscular dystrophy, Progeria, Lonafarnib, HGPS

PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call onThursday, August 5, 2021at4:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021.

Key Points: 
  • PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call onThursday, August 5, 2021at4:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021.
  • Eigeris a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
  • Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.
  • Zokinvyfor the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product.

Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Organic compounds, Chemical compounds, Senescence, Chloroarenes, Orphan drugs, Breakthrough therapy, Lonafarnib, Organobromides, Progeria, Laminopathy, Prenylation

To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 1090136.

Key Points: 
  • To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 1090136.
  • Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.
  • Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.\nZokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies is the Company's first FDA approved product.
  • A Marketing Authorization Application (MAA) is under review by theEuropean Medicines Agency(EMA).\nFor additional information about Eiger and its clinical programs, please visit www.eigerbio.com .\n"

Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies

Retrieved on: 
Monday, January 25, 2021
Branches of biology, Senescence, Health, Genodermatoses, Rare diseases, Progeroid syndromes, Laminopathy, Muscular dystrophy, Lonafarnib, Progeria, HGPS, Lamin

Zokinvy blocks the accumulation of defective, farnesylated proteins which formtightassociationswiththenuclearenvelope,leadingtocellularinstability and the process of premature aging in children and young adults with Progeria and processing-deficient Progeroid Laminopathies.

Key Points: 
  • Zokinvy blocks the accumulation of defective, farnesylated proteins which formtightassociationswiththenuclearenvelope,leadingtocellularinstability and the process of premature aging in children and young adults with Progeria and processing-deficient Progeroid Laminopathies.
  • Progeria, also known as HutchinsonGilford Progeria Syndrome(HGPS), and Progeroid Laminopathies are separate and distinct ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients.
  • It is estimated that there are 400 children worldwide with Progeria and 200 children with Progeroid Laminopathies.
  • Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies is the Company's first FDA approval.

Breakthrough Study Supports Genetic Editing as a Potential Treatment for Rare Rapid-Aging Disease Progeria

Retrieved on: 
Wednesday, January 6, 2021
Senescence, Progeroid syndromes, Genodermatoses, Rare diseases, Health, Organic compounds, Progeria, Sam Berns, Lonafarnib, Berns, Life According to Sam, Laminopathy

Without the FDA-approved treatment Zokinvy (lonafarnib), children with Progeria die of heart disease at an average age of 14.5 years, due to premature atherosclerosis resulting in heart attacks.

Key Points: 
  • Without the FDA-approved treatment Zokinvy (lonafarnib), children with Progeria die of heart disease at an average age of 14.5 years, due to premature atherosclerosis resulting in heart attacks.
  • Zokinvy increases average lifespan by 2.5 years and improves some symptoms of Progeria, but it does not address the genetic mutation that causes the disease.
  • Using a newer form of genetic editing, known as base editing, researchers found that they could reverse the mutation that causes Progeria, improving disease symptoms and dramatically increasing lifespan in a Progeria mouse model.
  • The Progeria Research Foundation (PRF) is a nonprofit organization established in 1999 by the family of Sam Berns, a child with Progeria.